Scienture (SCNX) Set to Release Quarterly Earnings on Wednesday

Scienture (NASDAQ:SCNX) is projected to post its Q3 2026 resultson Wednesday, November 11th. Analysts expect Scienture to post earnings of ($1.57) per share and revenue of $1.22 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Scienture (NASDAQ:SCNX) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($2.25) by $2.18. The firm had revenue of $0.34 million during the quarter, compared to analyst estimates of $1.96 million. On average, analysts expect Scienture to post ($4.44) EPS for the current fiscal year and ($0.27) EPS for the next fiscal year.

Scienture Trading Up 6.8%

Shares of SCNX stock opened at $3.45 on Wednesday. Scienture has a 12 month low of $2.64 and a 12 month high of $27.75. The stock has a 50 day moving average of $6.02 and a two-hundred day moving average of $9.12. The company has a current ratio of 3.04, a quick ratio of 2.97 and a debt-to-equity ratio of 0.15.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on SCNX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Scienture in a research note on Monday, September 21st. Zacks Research upgraded shares of Scienture to a “hold” rating in a research note on Friday, October 2nd. Finally, Maxim Group set a $6.00 price target on shares of Scienture and gave the company a “buy” rating in a report on Friday, October 23rd. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $6.00.

Scienture Company Profile

Scienture Holdings, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for central nervous system disorders. The company seeks to address unmet treatment needs through pharmaceutical products and drug-delivery technologies designed to improve patient convenience and therapeutic use.

Scienture’s areas of interest include conditions such as insomnia, attention-deficit/hyperactivity disorder, anxiety, depression and pain. Its portfolio includes product candidates and commercial opportunities involving alternative delivery formats, including oral formulations and sprays.

The company serves the pharmaceutical market primarily in the United States.